Copper histidinate - Generic Drug Details

What are the generic sources for copper histidinate and what is the scope of freedom to operate?

Copper histidinate is the generic ingredient in one branded drug marketed by Sentynl Theraps Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for copper histidinate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Patent Applications:	103
What excipients (inactive ingredients) are in copper histidinate?	copper histidinate excipients list
DailyMed Link:	copper histidinate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for copper histidinate

Constraining patent/regulatory exclusivity:

TREATMENT OF MENKES DISEASE IN PEDIATRIC PATIENTS

Dosage:

POWDER;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for copper histidinate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Stephen G. Kaler, MD	Phase 1/Phase 2
National Center for Complementary and Integrative Health (NCCIH)	Phase 3
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3

See all copper histidinate clinical trials

US Patents and Regulatory Information for copper histidinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sentynl Theraps Inc	ZYCUBO	copper histidinate	POWDER;SUBCUTANEOUS	211241-001	Jan 12, 2026		RX	Yes	Yes
Sentynl Theraps Inc	ZYCUBO	copper histidinate	POWDER;SUBCUTANEOUS	211241-001	Jan 12, 2026		RX	Yes	Yes

Market Dynamics and Financial Trajectory for Copper Histidinate

Last updated: March 8, 2026

Is Copper Histidinate Approved and Commercialized?

Copper histidinate remains an experimental compound with no widespread regulatory approval. It is primarily in preclinical or early clinical phases. No major pharmaceutical company has announced commercialization or patenting of copper histidinate as a licensed drug.

What Are the Clinical Indications and Research Status?

Copper histidinate is primarily studied for copper deficiency management and related metabolic disorders. Current research is limited to preclinical trials focusing on its pharmacokinetics, safety, and biological activity. No robust efficacy data or large-scale clinical trials support its use.

How Does Its Market Position Compare with Similar Compounds?

Compared to established copper supplements such as copper sulfate and copper gluconate, copper histidinate offers potentially improved bioavailability and targeted delivery. However, these theoretical advantages lack validation through extensive research or clinical data.

What Are the Patent and Regulatory Barriers?

Patent filings related to copper histidinate remain sparse. Without patented formulations or approved therapeutic indications, commercialization faces significant hurdles. Regulatory pathways would demand comprehensive safety and efficacy data, which are currently lacking.

What Are the Economic and Investment Implications?

The lack of regulatory approval and clinical maturity imply limited immediate commercial prospects. Venture capital and pharmaceutical investment in copper histidinate focus on early-stage research, with high risk due to technical and regulatory uncertainties. Market size remains undefined, as the compound has no approved therapeutic indication.

How Do Competitive and Market Trends Affect Future Trajectory?

Market trends favor gene therapies and targeted treatments over mineral supplements, reducing the potential for growth in this area. With existing copper supplementation options meeting current medical needs, copper histidinate lacks competitive advantage without proven benefits.

Summary of Financial Outlook

Factor	Status	Impact on Market Potential
Regulatory Approval	None	Limits commercialization
Clinical Data	None	Hinders clinical adoption
Patent Protection	Limited/None	Reduces exclusivity and investment appeal
Market Competition	High (copper salts)	Competes with established, low-cost options
Research Funding	Limited	Restricts development and validation

Key Challenges and Opportunities

Challenges:

• Lack of clinical validation
• Regulatory uncertainties
• Competition from established copper supplements

Opportunities:

• Niche application in specific metabolic conditions if validated
• Potential for formulation patents with bioavailability advantages

Key Takeaways

• Copper histidinate remains an experimental compound with no approved or marketed therapeutic applications.
• Its research is limited to early-stage preclinical studies focusing on biological activity.
• The compound faces significant regulatory, patent, and market entry barriers.
• Market prospects are constrained by competition from established copper supplements and lack of clinical validation.
• Investment and commercial development depend on emerging clinical data and successful demonstration of therapeutic benefits.

FAQs

Q1: Is copper histidinate approved by any health authorities?
A1: No, it is not approved for medical use by agencies such as the FDA or EMA.

Q2: What is the primary intended use for copper histidinate?
A2: Currently, it is studied for copper deficiency and related metabolic disorders, but no approved indications exist.

Q3: Are there patent protections for copper histidinate?
A3: Limited patent filings exist; substantial patent protection is absent.

Q4: How does copper histidinate compare to other copper supplements?
A4: Theoretically, it offers improved bioavailability, but lacks validation through clinical trials.

Q5: What is the outlook for financial investment?
A5: High risk due to early-stage research and regulatory barriers, with limited near-term commercial potential.